Arsenic in drinking water and bladder cancer

Cancer Investigation

Volumn 18, Issue 2, 2000, Pages 174-182

  Steinmaus, Craig ^a   Moore, Lee ^a   Hopenhayn Rich, Claudia ^b   Biggs, Mary Lou ^a   Smith, Allan H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; DRINKING WATER;

ARTICLE; BLADDER CANCER; CANCER RISK; CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; POLLUTION; PRIORITY JOURNAL; RISK ASSESSMENT; TAIWAN;

EID: 0034004681     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009038249     Document Type: Article

References (47)

1. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Metals and Metallic Compounds, Vol. 23, Lyon, International Agency for Research on Cancer, 1980.
2. Smith AH, Goycolea M, Haque R, et al: Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660-669, 1998.
3. Tsuda T, Babazono A, Yamamoto E, et al: Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am J Epidemiol 141:198-209, 1995.
4. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al: Bladder cancer mortality associated with arsenic in drinking water in Argentina [see comments] [published erratum appears in Epidemiology 8: 334, 1997]. Epidemiology 7:117-124, 1996.
5. Guo H, Chiang H, Hu H, et al: Arsenic in drinking water and incidence of urinary cancers. Epidemiology 8:545-550, 1997.
6. Chen CJ, Kuo TL, Wu MM: Arsenic and cancer [letter]. Lancet 1:414-415, 1988.
7. Chen C, Chuang Y, You S, et al: A retrospective study on malignant neoplasms of bladder, lung and liver in Blackfoot endemic area of Taiwan. Br J Cancer 53:399-405, 1986.
8. Cuzick J, Sasieni P, Evans S: Ingested arsenic, keratoses, and bladder cancer. Am J Epidemiol 136:417-421, 1992.
9. Chen CJ, Chen CW, Wu MM, et al: Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888-892, 1992.
10. Smith AH, Hopenhayn-Rich C, Bates MN, et al: Cancer risks from arsenic in drinking water [see comments]. Environ Health Perspect 97:259-267, 1992.
11. Jager J, Ostrosky-Wegman P. Arsenic: a paradoxical human carcinogen. Mutat Res 386:181-184, 1997.
12. Science Applications International Corporation: Estimated national occurrence and exposure to arsenic in public drinking water supplies. Revised draft, prepared for the U.S. Environmental Protection Agency under contract No. 69-01-766. Washington, DC, EPA, 1987.
13. Tseng W: Effects and dose-relationships of skin cancer and Blackfoot disease with arsenic. Environ Health Perspect 19:109-119, 1977.
14. Tseng WP, Chu HM, How SW, et al: Prevalence of skin cancer in an endemic area of chronic arsenicalism in Taiwan. J Natl Cancer Inst 40:453-463, 1968.
15. Chiou HY, Hsueh YM, Liaw KF, et al: Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55:1296-1300, 1995.
16. Chen C, Wang C: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50:5470-5475, 1990.
17. Chen CJ, Wu MW, Lee SS, et al: Atherogenicity and carcinogenicity of high-arsenic artesian well water: multiple risk factors and related malignant neoplasms of Blackfoot disease. Arteriosclerosis 8:452-460, 1988.
18. Chen CJ, Chuang Y-C, Lin T-M, et al: Malignant neoplasms among residents of a Blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45: 5895-5899, 1985.
19. Carlson-Lynch H, Beck BD, Boardman PD. Arsenic risk assessment [see comments]. Environ Health Perspect 102:354-356, 1994.
20. Lu F. Blackfoot disease: arsenic or humic acid. Lancet 336:115-116, 1990.
21. International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of the IARC Monographs, Volumes 1 to 42, Supplement 7, Lyon, International Agency for Research on Cancer, 1987.
22. Larson C: Historical development of the national primary drinking water regulations. In: Safe Drinking Water Act: Amendments, Regulations, and Standards, edited by E Calabrese, C Gilbert, H Pastides, Chelsea, MI, Lewis Publishers, 1989, pp. 3-15.
23. Wong O, Whorton M, Foliart D, et al: An ecological study of skin cancer and environmental arsenic exposure. Int Arch Occup Health 64:235-241, 1992.
24. Southwick J, Western A, Beck M, et al: An epidemiological investigation of arsenic in drinking water in Millard County, Utah. In: Arsenic: Industrial, Biochemical, and Environmental Perspectives, Proceedings Arsenic Symposium, edited by W Lederer, R Fensterheim. New York, Van Nostrand Reinhold. 1983, pp. 210-215.
25. Morton W, Starr G, Pohl D, et al: Skin cancer and water arsenic in Lane County, Oregon. Cancer 37:2523-2532, 1976.
26. U.S. Environmental Protection Agency: Special Report on Inorganic Arsenic: Skin Cancer; Nutritional Essentiality, EPA 625/3-87/013, Washington, DC, EPA Risk Assessment Forum, 1988.
27. World Health Organization: Guidelines for Drinking Water Quality: Recommendations. 1, Geneva, World Health Organization, 1993.
28. Roberson J, Neukrug H: The water industry perspective on the important arsenic regulatory issues. In: Arsenic: Exposure and Health, edited by W Chappel, C Abernathy, C Cothern, Northwood, Science and Technology Letters, 1994, pp. 289-294.
29. Abernathy CO, Chappell WR, Meek ME, et al: Is ingested inorganic arsenic a "threshold" carcinogen? Fundam Appl Toxicol 29:168-175, 1996.
30. Slayton TM, Barbara B, Reynolds K, et al: Issues in arsenic cancer risk assessment. Environ Health Sciences 104:1012-1014, 1996.
31. Hopenhayn-Rich C, Smith AH, Goeden HM. Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ Res 60:161-77, 1993.
32. Hsueh YM, Huang YL, Huang CC, et al: Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health 54:431-444, 1998.
33. Kurttio P, Komulainen H, Hakala E, et al: Urinary excretion of arsenic species after exposure to arsenic present in drinking water. Arch Environ Contam Toxicol 34:297-305, 1998.
34. Warner ML, Moore LE, Smith MT, et al: Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol Biomarkers Prev 3:583-590, 1994.
35. Thompson D: A chemical hypothesis for arsenic methylation in mammals. Chem Biol Interact 88:89-114, 1993.
36. Del Razo LM, Garcia-Vargas GG, Vargas H, et al: Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch Toxicol 71:211-217, 1997.
37. Hopenhayn-Rich C, Biggs ML, Smith AH, et al: Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620-628, 1996.
38. Vahter M, Marafante E: Effects of low dietary intake of methionine, choline, and proteins of the biotransformation of arsenite in the rabbit. Toxicol Lett 37:41-46, 1987.
39. Mushak P, Crocetti AF: Risk and revisionism in arsenic cancer risk assessment [see comments]. Environ Health Perspect 103: 684-689, 1995.
40. Yang T, Blackwell R: Nutritional and environmental conditions in the Blackfoot area. Formosan Sci 15:101-129, 1961.
41. Engel RR, Receveur O: Arsenic ingestion and internal cancers. Am J Epidemiol 138:896-897, 1993.
42. Moore LE, Smith AH, Hopenhayn-Rich C, et al: Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water. Cancer Epidemiol Biomarkers Prev 6: 31-36, 1997.
43. Gonsebatt ME, Vega L, Salazar AM, et al: Cytogenetic effects in human exposure to arsenic. Mutat Res 386:219-228, 1997.
44. Moore L, Smith A, Hopenhayn-Rich C, et al: Decrease in bladder cell micronucleus prevalence after intervention to lower the concentration of arsenic in drinking water. Cancer Epidemiol Biomark Prev 6:1051-1056, 1997.
45. Oya-Ohta Y, Kaise T, Ochi T: Induction of chromosomal aberrations in cultured human fibroblasts by inorganic and organic arsenic compounds and the different roles of glutathione in such induction. Mutat Res 357:123-129, 1996.
46. Huang H, Huang C, Wu C, et al: Glutathione as a cellular defense against arsenite toxicity in cultured Chinese hamster ovary cells. Toxicology 79:195-204, 1993.
47. Chiou HY, Hsueh YM, Hsieh LL, et al: Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res 386:197-207, 1997.